Maze Therapeutics Insider Sells 72,500 Shares for $2.94 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy MAZE?
Source: NASDAQ.COM
- Insider Transaction: Atul Dandekar, Chief Strategy Officer of Maze Therapeutics, exercised 72,500 shares and immediately sold them for approximately $2.94 million, indicating a strategic liquidity management approach during the clinical stage.
- Option Exercise: The transaction was executed at a weighted average purchase price of $40.56 as per SEC Form 4, suggesting that Dandekar's sale does not alter the company's strategic outlook.
- Financial Position: Maze Therapeutics reported $383.9 million in cash and marketable securities at the end of Q3, providing sufficient runway to fund operations into 2028, highlighting its financial stability for upcoming clinical trials.
- Market Reaction: Although Dandekar's direct holdings decreased by approximately 87%, Maze's stock surged 150% over the past year, reflecting investor optimism regarding the company's future clinical trial outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MAZE is 51.33 USD with a low forecast of 42.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.950
Low
42.00
Averages
51.33
High
60.00
Current: 43.950
Low
42.00
Averages
51.33
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Maze Therapeutics Executive Stock Transaction
- Executive Stock Transaction: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them on January 22, 2026, for approximately $227,612, indicating proactive management of executive stock holdings.
- Ownership Change: Following the transaction, Bachrodt's direct holdings decreased to 12,965 shares, representing 0.0269% of Maze Therapeutics' outstanding shares, reflecting confidence in the company's future and risk management strategy.
- Compliance with Trading Plan: The stock sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to schedule trades in advance, ensuring compliance and transparency in the transaction.
- Market Performance Outlook: Since its IPO on January 31, 2025, Maze Therapeutics' stock surged 158% in 2025, and while it continues to rise in early 2026, investors should be cautious of potential short-term pullbacks, although the long-term outlook remains promising, particularly with advancements in clinical trials for kidney and metabolic diseases.
See More
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year
- Executive Transaction Overview: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them on January 22, 2026, for approximately $227,612, indicating executive confidence in the company's stock performance.
- Ownership Change Analysis: Following this transaction, Bachrodt's direct holdings decreased to 12,965 shares, representing 0.0269% of Maze Therapeutics' outstanding shares, reflecting a cautious stance towards the company's future developments.
- Compliance with Trading Plan: The stock sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to schedule share transactions in advance, ensuring compliance and transparency in the trading process.
- Market Performance Outlook: Since its IPO on January 31, 2025, Maze Therapeutics' stock has surged 158% in 2025, and while it continues to rise in early 2026, investors should be wary of potential short-term pullbacks to better capitalize on long-term growth opportunities.
See More
Maze Therapeutics Stock Surges 157% in 2025
- Executive Stock Transaction: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them for approximately $227,612 on January 22, 2026, indicating strong executive confidence in the company's future prospects.
- Stock Surge: Following its IPO, Maze Therapeutics' stock surged 157% in 2025, achieving nine consecutive months of gains after its market debut, reflecting robust market recognition of its clinical-stage drugs.
- Clinical Advancements: The company is advancing its drug candidates targeting kidney and metabolic diseases into later clinical stages, which are expected to generate significant revenue once trials are completed, further bolstering investor confidence.
- Market Outlook: While there may be short-term drawdown risks, the long-term growth potential of Maze Therapeutics remains strong, attracting investor interest, especially as its drug development progresses.
See More
MAZE Options Analysis: $40 Put Option Offers 9% Potential YieldBoost
- Put Option Yield: The current bid for the $40.00 put option is $3.60, and if an investor sells this contract, they commit to buying the stock at $40.00, resulting in a cost basis of $36.40, which represents a 9% discount to the current price of $43.80, making it an attractive alternative.
- Expiration Risk Analysis: There is a 67% chance that the put option will expire worthless, in which case the premium would yield a 9% return on the cash commitment, equating to an annualized return of 56.68%, highlighting the potential appeal of this investment strategy.
- Covered Call Strategy: The $45.00 call option has a current bid of $5.60, and if an investor buys MAZE shares at $43.80 and sells this call, they could achieve a total return of 15.53% if the stock is called away at expiration, showcasing the profit potential of this approach.
- Market Volatility: Both the put and call options have an implied volatility of approximately 119%, while the actual trailing twelve-month volatility is 93%, indicating a high market expectation for price fluctuations in MAZE stock, which investors should carefully assess for risk.
See More
Maze Therapeutics' Atul Dandekar Sells 72,500 Shares for $2.94 Million
- Executive Transaction Overview: Atul Dandekar, Chief Strategy Officer of Maze Therapeutics, executed an option exercise and immediately sold 72,500 shares for approximately $2.94 million, indicating a strategic approach to liquidity management by company executives.
- Change in Ownership Proportion: This transaction reduced Dandekar's direct holdings from 83,003 shares to 10,503 shares, a decrease of 87.35%, which may reflect a potential shift in his confidence regarding the company's future prospects.
- Financial Condition Analysis: Maze Therapeutics reported $383.9 million in cash and marketable securities at the end of Q3, providing sufficient runway to fund operations into 2028, showcasing the company's financial robustness in its clinical stage.
- Market Reaction Expectations: Although Dandekar's transaction may be viewed as a liquidity event, Maze's stock has surged 150% over the past year, indicating strong investor optimism regarding the company's upcoming clinical trials.
See More
Maze Therapeutics Insider Sells 72,500 Shares for $2.94 Million
- Insider Transaction: Atul Dandekar, Chief Strategy Officer of Maze Therapeutics, exercised 72,500 shares and immediately sold them for approximately $2.94 million, indicating a strategic liquidity management approach during the clinical stage.
- Option Exercise: The transaction was executed at a weighted average purchase price of $40.56 as per SEC Form 4, suggesting that Dandekar's sale does not alter the company's strategic outlook.
- Financial Position: Maze Therapeutics reported $383.9 million in cash and marketable securities at the end of Q3, providing sufficient runway to fund operations into 2028, highlighting its financial stability for upcoming clinical trials.
- Market Reaction: Although Dandekar's direct holdings decreased by approximately 87%, Maze's stock surged 150% over the past year, reflecting investor optimism regarding the company's future clinical trial outcomes.
See More
Analysis of Maze Therapeutics Executive Stock Transaction
- Executive Stock Transaction: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them on January 22, 2026, for approximately $227,612, indicating proactive management of executive stock holdings.
- Ownership Change: Following the transaction, Bachrodt's direct holdings decreased to 12,965 shares, representing 0.0269% of Maze Therapeutics' outstanding shares, reflecting confidence in the company's future and risk management strategy.
- Compliance with Trading Plan: The stock sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to schedule trades in advance, ensuring compliance and transparency in the transaction.
- Market Performance Outlook: Since its IPO on January 31, 2025, Maze Therapeutics' stock surged 158% in 2025, and while it continues to rise in early 2026, investors should be cautious of potential short-term pullbacks, although the long-term outlook remains promising, particularly with advancements in clinical trials for kidney and metabolic diseases.
See More
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year
- Executive Transaction Overview: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them on January 22, 2026, for approximately $227,612, indicating executive confidence in the company's stock performance.
- Ownership Change Analysis: Following this transaction, Bachrodt's direct holdings decreased to 12,965 shares, representing 0.0269% of Maze Therapeutics' outstanding shares, reflecting a cautious stance towards the company's future developments.
- Compliance with Trading Plan: The stock sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to schedule share transactions in advance, ensuring compliance and transparency in the trading process.
- Market Performance Outlook: Since its IPO on January 31, 2025, Maze Therapeutics' stock has surged 158% in 2025, and while it continues to rise in early 2026, investors should be wary of potential short-term pullbacks to better capitalize on long-term growth opportunities.
See More
Maze Therapeutics Stock Surges 157% in 2025
- Executive Stock Transaction: Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised 5,000 options and sold them for approximately $227,612 on January 22, 2026, indicating strong executive confidence in the company's future prospects.
- Stock Surge: Following its IPO, Maze Therapeutics' stock surged 157% in 2025, achieving nine consecutive months of gains after its market debut, reflecting robust market recognition of its clinical-stage drugs.
- Clinical Advancements: The company is advancing its drug candidates targeting kidney and metabolic diseases into later clinical stages, which are expected to generate significant revenue once trials are completed, further bolstering investor confidence.
- Market Outlook: While there may be short-term drawdown risks, the long-term growth potential of Maze Therapeutics remains strong, attracting investor interest, especially as its drug development progresses.
See More
MAZE Options Analysis: $40 Put Option Offers 9% Potential YieldBoost
- Put Option Yield: The current bid for the $40.00 put option is $3.60, and if an investor sells this contract, they commit to buying the stock at $40.00, resulting in a cost basis of $36.40, which represents a 9% discount to the current price of $43.80, making it an attractive alternative.
- Expiration Risk Analysis: There is a 67% chance that the put option will expire worthless, in which case the premium would yield a 9% return on the cash commitment, equating to an annualized return of 56.68%, highlighting the potential appeal of this investment strategy.
- Covered Call Strategy: The $45.00 call option has a current bid of $5.60, and if an investor buys MAZE shares at $43.80 and sells this call, they could achieve a total return of 15.53% if the stock is called away at expiration, showcasing the profit potential of this approach.
- Market Volatility: Both the put and call options have an implied volatility of approximately 119%, while the actual trailing twelve-month volatility is 93%, indicating a high market expectation for price fluctuations in MAZE stock, which investors should carefully assess for risk.
See More
Maze Therapeutics' Atul Dandekar Sells 72,500 Shares for $2.94 Million
- Executive Transaction Overview: Atul Dandekar, Chief Strategy Officer of Maze Therapeutics, executed an option exercise and immediately sold 72,500 shares for approximately $2.94 million, indicating a strategic approach to liquidity management by company executives.
- Change in Ownership Proportion: This transaction reduced Dandekar's direct holdings from 83,003 shares to 10,503 shares, a decrease of 87.35%, which may reflect a potential shift in his confidence regarding the company's future prospects.
- Financial Condition Analysis: Maze Therapeutics reported $383.9 million in cash and marketable securities at the end of Q3, providing sufficient runway to fund operations into 2028, showcasing the company's financial robustness in its clinical stage.
- Market Reaction Expectations: Although Dandekar's transaction may be viewed as a liquidity event, Maze's stock has surged 150% over the past year, indicating strong investor optimism regarding the company's upcoming clinical trials.
See More
Maze Therapeutics Insider Sells 72,500 Shares for $2.94 Million
- Insider Transaction: Atul Dandekar, Chief Strategy Officer of Maze Therapeutics, exercised 72,500 shares and immediately sold them for approximately $2.94 million, indicating a strategic liquidity management approach during the clinical stage.
- Option Exercise: The transaction was executed at a weighted average purchase price of $40.56 as per SEC Form 4, suggesting that Dandekar's sale does not alter the company's strategic outlook.
- Financial Position: Maze Therapeutics reported $383.9 million in cash and marketable securities at the end of Q3, providing sufficient runway to fund operations into 2028, highlighting its financial stability for upcoming clinical trials.
- Market Reaction: Although Dandekar's direct holdings decreased by approximately 87%, Maze's stock surged 150% over the past year, reflecting investor optimism regarding the company's future clinical trial outcomes.
See More
